Goldman Sachs Call 180 CHKP 21.06.../ DE000GG7AF47 /
| 6/7/2024 11:44:15 AM | Chg.0.000 | Bid10:00:43 PM | Ask10:00:43 PM | Underlying | Strike price | Expiration date | Option type |
|---|---|---|---|---|---|---|---|
| 0.001EUR | 0.00% | - Bid Size: - |
- Ask Size: - |
Check Point Software... | 180.00 USD | 6/21/2024 | Call |
GlobeNewswire
6/6
Scientific Journal Reports Findings that Show LIXTE’s Lead Clinical Compound, LB-100, Increases Reco...
GlobeNewswire
6/6
Shattuck Labs to Host Investor Call and Webcast on Additional Interim Data Presented at the European...
GlobeNewswire
6/6
CHECKPOINT ALERT: Bragar Eagel & Squire, P.C. is Investigating Checkpoint Therapeutics, Inc. on Beha...
GlobeNewswire
6/5
Ocean Biomedical (NASDAQ: OCEA) Congratulates Joint Venture Partner, Virion Therapeutics, on Positiv...
GlobeNewswire
6/5
OSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating FR...
GlobeNewswire
6/4
DEADLINE TODAY: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losse...
GlobeNewswire
6/4
Indaptus Therapeutics to Present New Positive Data on Decoy20 at Next-Gen Immuno-Oncology Conference
GlobeNewswire
6/4
CKPT DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages Checkpoint Therapeutics, Inc. Investor...
GlobeNewswire
6/3
Ascendis Pharma Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024
GlobeNewswire
6/3
7 Hills Pharma Receives $4.7MM Grant to Advance First-in-class Cell/Gene Therapy Technology into the...
GlobeNewswire
6/3
DEADLINE ALERT for CKPT, OCGN, SOND, QDEL: Law Offices of Howard G. Smith Reminds Investors of Class...
GlobeNewswire
6/3
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ch...
GlobeNewswire
6/3
DEADLINE ALERT for HRT and CKPT: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions...
GlobeNewswire
6/3
CKPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Checkpoint Therapeutics, Inc. ...
GlobeNewswire
6/3
ORYZON Announces Journal Publication of Final Phase IIa ALICE Results with Iadademstat in The Lancet...
GlobeNewswire
6/2
ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1...
GlobeNewswire
6/2
Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT...
GlobeNewswire
6/1
Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pret...
GlobeNewswire
6/1
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates M...
GlobeNewswire
6/1
Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monothera...
